NANOBIOTIX Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development and Director of Investor Relati...
October 03 2016 - 3:39PM
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late
clinical-stage nanomedicine company pioneering novel approaches for
the local treatment of cancer, today announced that it has
strengthened its U.S. leadership team with the appointments of Dr.
Mihail Obrocea as the Head of U.S. Clinical Development and Noel
Kurdi as the Director of Investor Relations.
These high level profiles will contribute to
reinforce Nanobiotix's presence in the US by strengthening its
clinical development and by leveraging US investors potential to
continue the growth of the Company.
In the US, Nanobiotix has successfully filed its
Investigational New Drug application (IND) for NBTXR3 for the
treatment of prostate cancer and plans to initiate a Phase I/II
trial in three U.S. based oncology sites. In parallel, the Company
continues to advance the development its lead product in multiple
oncology indications across the world.
Nanobiotix incorporated an affiliate in
Cambridge in 2014, and opens a new office today in New York City,
in order to increase the Company's visibility and be accessible to
the financial community.
Dr. Mihail Obrocea joined Nanobiotix from
U.S.-based SFJ Pharmaceuticals Group, where he held the position of
Vice President of Clinical & Medical Affairs. Previously, he
served as Project Director and Oncology Clinical Lead at AbbVie
Biotherapeutics Corp., leading multiple Phase I and II oncology and
hematology clinical trials. He also held the position of Vice
President and Head of Clinical Development Oncology at MannKind
Corp. where he brought two cancer vaccines programs into the
clinical stages. He has held clinical leadership positions at
Sigma-Tau Research and MedImmune. Dr. Obrocea earned his M.D.
from the School of Medicine and Pharmacy in Bucharest, Romania. He
completed an internal medicine residency at Yale University School
of Medicine in Connecticut and completed a hematology / oncology
fellowship at Dartmouth Medical School in New Hampshire.
Noel Kurdi joined Nanobiotix from the Trout
Group & Trout Capital, where she served as a Senior Associate,
providing strategic investor relations counsel to US based and
multinational biotech companies seeking access to the US and
international capital markets. Previously, Kurdi worked in
institutional equity sales and research at Brean Capital, LLC, and
held capital markets, business development and investor relations
roles at AIG investments. She earned her M.B.A. in finance and
marketing from Fordham University and a B.B.A. in international
business and marketing from George Washington University.
-Ends-
About NANOBIOTIX: Nanobiotix (Euronext: NANO / ISIN:
FR0011341205) is a late clinical-stage nanomedicine company
pioneering novel approaches for the local treatment of cancer. The
Company's first-in-class, proprietary technology, NanoXray,
enhances radiotherapy energy with a view to provide a new, more
efficient treatment for cancer patients.
NanoXray products are compatible with current
radiotherapy treatments and are meant to treat potentially a wide
variety of solid tumors including soft tissue sarcoma, head and
neck cancers, liver cancers, prostate cancer, breast cancer,
glioblastoma, etc., via multiple routes of administration.
Nanobiotix's lead product NBTXR3, based on
NanoXray, is currently under clinical development for soft tissue
sarcoma, head and neck cancer, prostate cancer, rectal cancer
(PharmaEngine) and liver cancers (HCC and liver metastases). The
Company has filed in August 2016 for market approval (CE Marking)
in Europe for its lead product NBTXR3. The Company has partnered
with PharmaEngine for clinical development and commercialization of
NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of
Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO,
Bloomberg: NANO: FP). The Company Headquarter is based in Paris,
France. Affiliate in Cambridge, United States.
For more information, please visit
www.nanobiotix.com
Contact
Nanobiotix |
|
|
Sarah Gaubert Head of Communication and Public
Affairs +33 (0)1 40 26 07 55 contact@nanobiotix.com |
|
|
Media relations |
France -
NewCap Annie-Florence Loyer +33 (0)6 88 20 35 59
afloyer@newcap.fr |
|
EU
Outside France - Instinctif Partners Melanie Toyne
Sewell +44 (0) 207 457 2020 nanobiotix@instinctif.com |
United States -
The Ruth Group Kirsten Thomas / Chris Hippolyte +1
508-280-6592 / +1 646-536-7023 Nanobiotix@theruthgroup.com |
Disclaimer
This press release contains certain
forward-looking statements concerning Nanobiotix and its business.
Such forward-looking statements are based on assumptions that
Nanobiotix considers to be reasonable. However, there can be no
assurance that the estimates contained in such forward-looking
statements will be verified, which estimates are subject to
numerous risks including the risks set forth in the reference
document of Nanobiotix filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) under number D.16-0732
on July 22, 2016 (a copy of which is available on
www.nanobiotix.com) and to the development of economic conditions,
financial markets and the markets in which Nanobiotix operates. The
forward-looking statements contained in this press release are also
subject to risks not yet known to Nanobiotix or not currently
considered material by Nanobiotix. The occurrence of all or part of
such risks could cause actual results, financial conditions,
performance or achievements of Nanobiotix to be materially
different from such forward-looking statements.
This press release and the information that it
contains do not constitute an offer to sell or subscribe for, or a
solicitation of an offer to purchase or subscribe for, Nanobiotix
shares in any country.
Nanobiotix (EU:NANO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nanobiotix (EU:NANO)
Historical Stock Chart
From Jul 2023 to Jul 2024